This is a working overview of half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-15 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
==== MeSH E05.393.620 – nucleic acid amplification techniques ==== MeSH E05.393.620.311 – ligase chain reaction MeSH E05.393.620.374 – self-sustained sequence replication MeSH E05.393.620.500 – polymerase chain reaction MeSH E05.393.620.500.650 – primed in situ labeling MeSH E05.393.620.500.687 – random amplified polymorphic dna technique MeSH E05.393.620.500.725 – Reverse transcription polymerase chain reaction
==== Cancer ==== The first study on trained dogs used for the detection of cancer was published by Willis et al. in 2004, observing that dogs were capable of detecting bladder cancer from urine samples. Subsequently, in 2004, Pickel et al. confirmed that dogs were able to successfully diagnose melanoma. In 2008, Horvath et al. confirmed dogs were successful in differentiating between cancerous and normal tissue and in distinguishing non-cancerous pathological tissue from cancerous tissue. Another study by Horvath et al. in 2010 found the dogs to show over 90% specificity in detecting ovarian cancer from blood samples, colorectal cancer from respiratory air, and prostate cancer from dog urine.
== Target and events == The primary target of the doctrine was originally the largest communist country, the Soviet Union. However, additional targets also included the other communist countries like the China, Laos, Vietnam, and North Korea. After the dissolution of the Soviet Union in 1991 and China's economic prominence in the early 21st century, China became the major target of the doctrine.
Sources: en.wikipedia.org
{\displaystyle n_{\mathrm {A} }=n_{\mathrm {B} }{\frac {R_{\mathrm {B} }-R_{\mathrm {AB} }}{R_{\mathrm {AB} }-R_{\mathrm {A} }}}\times {\frac {x(^{j}\mathrm {A} )_{\mathrm {B} }}{x(^{j}\mathrm {A} )_{\mathrm {A} }}}}
== History == Before the advent of agriculture, humans were hunter-gatherers. They foraged for edible fruit, nuts, stems, leaves, corms, and tubers and hunted animals for food. Forest gardening in a tropical jungle clearing is thought to be the first example of agriculture; useful plant species were identified and encouraged to grow while undesirable species were removed. Plant breeding through the selection of strains with desirable traits such as large fruit and vigorous growth soon followed. While the first evidence for the domestication of grasses such as wheat and barley has been found in the Fertile Crescent in the Middle East, it is likely that various peoples around the world started growing crops in the period 10,000 BC to 7,000 BC. Subsistence agriculture continues to this day, with many rural farmers in Africa, Asia, South America, and elsewhere using their plots of land to produce enough food for their families, while any surplus produce is used for exchange for other goods. Throughout recorded history, the rich have been able to afford a varied diet including meat, vegetables and fruit, but for poor people, meat was a luxury and the food they ate was very dull, typically comprising mainly some staple product made from rice, rye, barley, wheat, millet or maize. The addition of vegetable matter provided some variety to the diet. The staple diet of the Aztecs in Central America was maize and they cultivated tomatoes, avocados, beans, peppers, pumpkins, squashes, peanuts, and amaranth seeds to supplement their tortillas and porridge.
==== Manufacturing process ==== After ingredients are combined, they are placed in a tank at the end of a canning machine. From there, the mixture is forced through an opening and onto a metal sheet, forming a thickness of 8 to 12mm. Next, the mixture is heated to thoroughly cook the ingredients. Heating can be done through the means of ovens, microwaves or steam heating. The sheet containing a layer of feed is passed through the heat source that displays heat to the top and bottom of the tray, allowing the internal temperature to reach 77 degrees Celsius at a minimum. Once cooked, this mixture can be directly placed into cans to form a loaf or it can be cut into "meaty" pieces for chunks and gravy formulas.
Sources: en.wikipedia.org
LEDs are used in mining operations, as cap lamps to provide light for miners. Research has been done to improve LEDs for mining, to reduce glare and to increase illumination, reducing risk of injury to the miners. LEDs are increasingly finding uses in medical and educational applications, for example as mood enhancement. NASA has even sponsored research for the use of LEDs to promote health for astronauts.
Ralph William James Rimmer. Lately Chief Executive Officer, Rugby Football League. For services to Rugby League Football. Dr. Lisa Margaret Ritchie. Head of Infection Prevention and Control, NHS England. For services to Healthcare, particularly during Covid-19. Michael Thomas Robinson. Chief Executive, Royal Scottish Geographical Society. For services to Climate Change Education. Professor Colva Mary Roney-Dougal. Professor of Mathematics, University of St Andrews. For services to Education and Mathematics. Kenneth James Gordon Harvey Ross. Founding Officer, National Down Syndrome Policy Group. For services to Charity, to Education and to People with Down Syndrome. Diane Rosalie Aldworth Ruddock. For services to the Environment, to Heritage and to the community in Northern Ireland. John Hamilton Ryley. Lately Head of News, Sky News. For services to Journalism. Clovis Constantine Salmon. Documentary Filmmaker. For services to Culture and to the Black Community. William Henry Salomon. President, Young Enterprise. For services to Education. Carolyn Margaret Sampson. Soprano. For services to Music. Steven Ross Savory. Chief Executive Officer, Gloucestershire Learning Alliance. For services to Education. Professor Ulrike Hermine Schmidt. Professor of Eating Disorders, King's College London and Consultant Psychiatrist, South London and Maudsley NHS Foundation Trust. For services to People with Eating Disorders. Ian Charles Sears. Commercial Specialist, Cabinet Office. For Public Service. Ruth Victoria Shaw. Chief Executive Officer, Premier League Charitable Fund.
A reference range in medicine is the range or the interval of values that is deemed normal for a physiological measurement in healthy persons (for example, the amount of creatinine in the blood, or the partial pressure of oxygen). It is a basis for comparison for a physician or other health professional to interpret a set of test results for a particular patient. Some important reference ranges in medicine are reference ranges for blood tests and reference ranges for urine tests.
==== Public opinion ==== Despite its growing notoriety in some circles, media stories generally suggest that the public at large are still mostly unaware of salvia, with the majority perhaps having never even heard of it. Although published responses may not necessarily be representative of public opinion as a whole, some news agencies generally support reader and viewer feedback in connection with their stories.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.